These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 8732061)

  • 21. Nitric oxide synthase (NOS3) and contractile responsiveness to adrenergic and cholinergic agonists in the heart. Regulation of NOS3 transcription in vitro and in vivo by cyclic adenosine monophosphate in rat cardiac myocytes.
    Belhassen L; Kelly RA; Smith TW; Balligand JL
    J Clin Invest; 1996 Apr; 97(8):1908-15. PubMed ID: 8621775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vesnarinone inhibits adenosine uptake in endothelial cells, smooth muscle cells and myocytes, and mediates cytoprotection.
    Kitakaze M; Fong M; Yoshitake M; Minamino T; Node K; Okuyama Y; Terada N; Kambayashi T; Hori M
    J Mol Cell Cardiol; 1997 Dec; 29(12):3413-7. PubMed ID: 9441846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcium sensitization in perfused beating guinea pig heart by a positive inotropic agent MCI-154.
    Abe Y; Ishisu R; Onishi K; Sekioka K; Narimatsu A; Nakano T
    J Pharmacol Exp Ther; 1996 Feb; 276(2):433-9. PubMed ID: 8632307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs.
    Vandeplassche GM; Hermans CF; de Chaffoy de Courcelles DR; D'Aubioul JA; Wouters LJ; De Clerck FF
    J Cardiovasc Pharmacol; 1992 May; 19(5):714-22. PubMed ID: 1381769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential response to vesnarinone by cardiac fibroblasts isolated from normal and aortic regurgitant hearts.
    Ross JS; Goldfine SM; Herrold EM; Borer JS
    Am J Ther; 1998 Nov; 5(6):369-75. PubMed ID: 10099079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of fluoride action on the L-type calcium channel in cardiac ventricular myocytes.
    Ono K; Arita M
    Cell Calcium; 1999; 26(1-2):37-47. PubMed ID: 10892569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological properties of the positive inotropic and alpha 1-adrenoceptor blocking agent saterinone.
    Armah BI; Hofferber E; Stenzel W
    Arzneimittelforschung; 1988 Sep; 38(9):1287-92. PubMed ID: 2906245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Ca2+ sensitizers on contraction, [Ca2+]i transient and myofilament Ca2+ sensitivity in diabetic rat myocardium: potential usefulness as inotropic agents.
    Ishitani T; Hattori Y; Sakuraya F; Onozuka H; Makino T; Matsuda N; Gando S; Kemmotsu O
    J Pharmacol Exp Ther; 2001 Aug; 298(2):613-22. PubMed ID: 11454923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of channel conductance by diacetyl monoxime in guinea pig and embryonic chick cardiomyocytes.
    Sada H; Ban T; Sperelakis N
    Zhongguo Yao Li Xue Bao; 1996 May; 17(3):201-6. PubMed ID: 9812734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positive inotropic activity of 5-amino-6-cyano-1,3-dimethyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrim idine-2,4-dione in cardiac muscle from guinea-pig and man. Part 6: Compounds with positive inotropic activity.
    Heber D; Heers C; Ravens U
    Pharmazie; 1993 Jul; 48(7):537-41. PubMed ID: 7692456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent.
    Sato S; Tomoyasu S; Okabe-Kado J; Hozumi M; Tsuruoka N; Nakai S; Adachi M; Honma Y
    Exp Hematol; 1996 Jan; 24(1):37-42. PubMed ID: 8536790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanical and electrophysiological effects of milrinone on the force-frequency relationship in mammalian myocardium.
    Mörner SE; Arlock P
    Acta Physiol Scand; 1994 Feb; 150(2):125-32. PubMed ID: 8191891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vesnarinone-mediated alterations of gene expression in cardiac fibroblasts from aortic regurgitant hearts.
    Truter SL; Dumlao TF; Lee JA; Lee E; Supino PG; Borer JS
    Am J Ther; 2004; 11(5):328-36. PubMed ID: 15356428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of vesnarinone on cytokine production and activation of murine microglia.
    Suzumura A; Sawada M
    Life Sci; 1999; 64(14):1197-203. PubMed ID: 10210262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Developmental aspects of electrophysiology in cardiac muscle].
    Satoh H; Sada H; Tohse N; Shigenobu K
    Nihon Yakurigaku Zasshi; 1996 May; 107(5):213-23. PubMed ID: 8690303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Influences of new synthetic drug vesnarinone on circulatory and respiratory function of dogs].
    Zhou Z; Lan T; Zha Z; Wang Y; Yang Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1991 Jun; 22(2):137-9. PubMed ID: 1786948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics of vesnarinone.
    Feldman AM
    Drug Saf; 2004; 27 Suppl 1():1-9. PubMed ID: 15293848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vesnarinone: a potential cytokine inhibitor.
    Sasayama S; Matsumori A
    J Card Fail; 1996 Sep; 2(3):251-8. PubMed ID: 8891863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety.
    Furusawa S; Ohashi Y; Asanoi H
    J Clin Pharmacol; 1996 May; 36(5):477-81. PubMed ID: 8739027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group.
    Soran O; Young JD; Holubkov R; Loftus S; Bourge R; Carson P; Jaski B; White BG; Feldman AM
    J Card Fail; 1999 Sep; 5(3):195-200; discussion 201-2. PubMed ID: 10496192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.